

## REMARKS


The Examiner stated the application was not in compliance with 37 CFR § 1.821 because sequence identifiers did not accompany sequence descriptions in Claim 4 and in the specification.

In response, applicants have amended Claim 4 and the specification by inserting sequence identifiers corresponding to the Sequence Disclosure to accompany sequence listings.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(609) 627-8507  
Date:

*July 17, 2006*

  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940